Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
$21.01
-$0.08(-0.43%)
At close: 4:00 PM EST
$21.01
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$16.00 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)530.48K
Market Cap
$944.04M
Enterprise Value$1.27B
Total Cash (Recent Filing)$445.86M
Total Debt (Recent Filing)$631.40M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Oct 30, 2025EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,932,720
10 Day Avg. Volume566,679
30 Day Avg. Volume530,484
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-2.80K
Forecast
1Y Price Target
$28.00Price Target Upside33.27% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Revenue GuidanceThe company narrowed its 2025 revenue guidance, indicating a more precise forecast.
Share Repurchase ProgramThe company has $250 million remaining in its share repurchase program.
Strategic PartnershipsA new co-promote partnership with J&J MedTech for Zilretta is anticipated to boost sales.
Bears Say
Market CompetitionPacira has been notified of an ANDA filing for gExparel from Qilu Pharmaceutical, which adds further uncertainty into the longer-term sustainability of Exparel sales.
Patent ChallengesThere is not enough momentum in Exparel sales growth in the near term to offset the negative sentiment from another patent/generic challenge.
Sales PerformanceThe sales growth of Exparel has been underwhelming under the NOPAIN Act thus far.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $16.00 and its highest was $27.64 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $944.04M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is today.
How were Pacira Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.65.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 44,932,720 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
Pacira Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.00 (33.27% Upside)
$28.00 (33.27% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 9.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $116.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.69%
12-Months-Change
Fundamentals
Return on Equity
-15.57%
Trailing 12-Months
Asset Growth
-6.65%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in EXPAREL volume growth, enhanced gross margins, strategic partnerships, and a strong financial position. However, there are concerns regarding stagnant sales for ZILRETTA and iovera°, increased operating expenses, and delays in the adoption of NOPAIN guidelines.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$28.00
▲(33.27% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
2.75% Insiders
24.81% Mutual Funds
1.15% Other Institutional Investors
39.70% Public Companies and
Individual Investors